Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03365947 |
Recruitment Status :
Completed
First Posted : December 8, 2017
Last Update Posted : April 26, 2021
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis B | Drug: ARO-HBV Injection Other: Sterile Normal Saline (0.9% NaCl) | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 114 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients |
Actual Study Start Date : | March 27, 2018 |
Actual Primary Completion Date : | April 23, 2020 |
Actual Study Completion Date : | April 23, 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: ARO-HBV Injection |
Drug: ARO-HBV Injection
Single or multiple doses of ARO-HBV Injection by subcutaneous (sc) injection |
Placebo Comparator: Placebo |
Other: Sterile Normal Saline (0.9% NaCl)
Calculated volume to match active comparator |
- Number of Participants With Adverse Events (AEs) Possibly or Probably Related to Treatment [ Time Frame: Up to 203 days ]
- Pharmacokinetics (PK) of ARO-HBV: Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Part A (single-ascending dose [SAD] phase) only: up to 48 hours post-dose ]
- PK of ARO-HBV: Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Part A (SAD phase) only: up to 48 hours post-dose ]
- PK of ARO-HBV: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) [ Time Frame: Part A (SAD phase) only: up to 48 hours post-dose ]
- PK of ARO-HBV: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf) [ Time Frame: Part A (SAD phase) only: up to 48 hours post-dose ]
- PK of ARO-HBV: Terminal Elimination Half-Life (t½) [ Time Frame: Part A (SAD phase) only: up to 48 hours post-dose ]
- Reduction of HBV Surface Antigen (HBsAg) from Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV [ Time Frame: Part B (multiple-ascending dose [MAD] phase) only: up to 113 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria for Parts A & B:
- Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception.
- Willing to provide written informed consent and comply with study requirements
Additional Inclusion Criteria for Part B:
- Diagnosis of chronic HBV infection
- HbsAg at screening > or = 50 IU/mL
- Liver Elastography score < or = 10.5
Exclusion Criteria:
- Clinically significant health concerns (with the exception of HBV for Patients in Part B)
- Abnormal for any clinical safety laboratory result considered clinically significant
- Regular use of alcohol within 1 month prior to screening
- Recent use of illicit drugs
- Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
NOTE: additional inclusion/exclusion criteria may apply, per protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03365947
Australia, New South Wales | |
Royal Prince Alfred Hospital | |
Camperdown, New South Wales, Australia, 2050 | |
Australia, Victoria | |
Monash Medical Centre | |
Clayton, Victoria, Australia, 3168 | |
St. Vincent's Hospital | |
Melbourne, Victoria, Australia, 3065 | |
Australia, Western Australia | |
Linear Research | |
Nedlands, Western Australia, Australia, 6009 | |
Hong Kong | |
Queen Mary Hospital | |
Hong Kong, Hong Kong | |
New Zealand | |
Auckland Clinical Studies Limited | |
Grafton, Auckland, New Zealand, 1010 | |
Middlemore Clinical Trials | |
Papatoetoe, Auckland, New Zealand, 2025 |
Responsible Party: | Arrowhead Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT03365947 |
Other Study ID Numbers: |
AROHBV1001 |
First Posted: | December 8, 2017 Key Record Dates |
Last Update Posted: | April 26, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Hepatitis A Hepatitis B Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Infections |
Enterovirus Infections Picornaviridae Infections RNA Virus Infections Blood-Borne Infections Communicable Diseases Hepadnaviridae Infections DNA Virus Infections |